Preliminary Outcomes of Quantitative Flow Ratio-Guided Coronary Bypass Grafting in Primary Valve Surgery: A Propensity Score Weighted Analysis

Jiaxi Zhu,James Tatoulis,Qiang Zhao
DOI: https://doi.org/10.1016/j.xjon.2024.06.008
2024-01-01
JTCVS Open
Abstract:Objectives The guidelines recommend fractional flow reserve (FFR)-guided coronary artery bypass grafting (CABG) during primary valve surgery without evidence. Quantitative flow ratio (QFR) is a novel coronary angiography (CAG)-based FFR. We aimed to compare the early clinical outcomes between QFR-guided and CAG-guided CABG in these patients. Methods This observational study screened all 2,081 patients admitted to our institution for elective primary mitral and/or aortic valve surgery from January 2017 to September 2020. Of them, all 188 patients with comorbid coronary artery lesions (visual estimated stenosis ≥ 50%) were included. Sixty-nine patients with QFR analysis received bypasses only for lesions with QFR ≤0.80 (QFR-guided group). The remaining 119 patients without QFR analysis received bypasses for all stenosis ≥ 50% (CAG-guided group). Propensity overlap weighting was used to neutralize the intergroup imbalance. The primary endpoint was MACE. Results After propensity score weighting, the baseline characteristics were comparable. Concomitant CABG was performed 58.1% vs 100% in QFR-guided and CAG-guided group, respectively. The mean number of grafts was significantly lower in QFR-guided group than in CAG-guided group (0.9±0.7 vs. 1.6±0.5; p<0.001). The weighted 30-day incidence of MACE was numerically lower in QFR-guided group than in CAG-guided group, but not statistically significant (6.3% vs 11.8%; p=0.429). After a median follow-up of 31.6 months, the weighted risk of MACE and mortality were significantly lower in QFR-guided group than in CAG-guided group (MACE: hazard ratio, 0.45; 95% CI, 0.24-0.84; p=0.012; mortality: hazard ratio, 0.38; 95% CI, 0.16-0.93; p=0.029). Conclusions Compared with CAG-guided CABG, QFR-guided CABG is associated with less grafting and better clinical outcome in primary valve surgery with comorbid coronary artery disease. To confirm this finding, the FAVOR IV-QVAS trial (NCT03977129) is on-going.
What problem does this paper attempt to address?